News

Benzinga.com9mon
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb's Cobenfy As First New Class Of Treatment In More Than 3 Decades - Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Cobenfy demonstrated statistically significant improvements in schizophrenia symptoms. Bristol Myers Squibb acquired Karuna Therapeutics' treatment in a $14 billion deal, marking a significant ...
C&EN9mon
FDA approves Cobenfy, a first-in-class schizophrenia drug
The US Food and Drug Administration has approved Cobenfy, also known as KarXT, a new schizophrenia treatment. The drug was developed by Karuna Therapeutics, which was bought by Bristol Myers ...
Hosted on MSN9mon
BMS wins approval for schizophrenia drug acquired from Karuna
Originally developed by Karuna Therapeutics and named KarXT, BMS inherited the drug as part of a $14bn acquisition, which was finalised in March 2024.
Time9mon
FDA Approves the First New Schizophrenia Drug in Decades
N o new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...
STAT9mon
FDA approves schizophrenia drug that could alter how disorder is treated
The drug, called Cobenfy, will be sold by Bristol Myers Squibb. It was developed by the biotech company Karuna Therapeutics, which Bristol acquired for $14 billion last year . advertisement ...
MedCity News9mon
FDA Approval of Bristol Myers Drug Makes It the First Novel Schizophrenia Med in Decades - MedCity News
The drug came from the pharma giant’s $14 billion acquisition of Karuna Therapeutics. By Frank Vinluan on September 27, 2024 2:19 pm. ... Cobenfy was developed in the labs of Karuna Therapeutics ...
FiercePharma9mon
BMS' schizophrenia gem Cobenfy was rescued from the scrapheap
Boston-based Karuna Therapeutics rolled the dice on xanomeline, licensing it from Lilly in 2012. In December of last year, BMS swooped in and bought out Karuna for $14 billion, convinced of KarXT ...
Hosted on MSN9mon
FDA approves a novel drug for schizophrenia, a potential ‘game changer’ - MSN
Based largely on Cobenfy’s promise, Bristol Myers Squibb paid $14 billion to acquire the company that developed the drug, Karuna Therapeutics, completing the acquisition March 18.
FiercePharma9mon
Bristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med Cobenfy
After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has borne fruit with the approval of a promising new drug. BMS’ first-in ...
Seeking Alpha9mon
Bristol-Myers Squibb: Cobenfy Approval A Major Coup For Dealmaker
Investment Overview — Background To Cobenfy Approval — Bristol-Myers Squibb's Buyout Of Karuna. Back in April 2020, I covered a company called Karuna Therapeutics in a note for Seeking Alpha ...
Nasdaq9mon
What Cobenfy Approval Means For Bristol Myers Squibb Stock
It acquired Mirati Therapeutics, RayzeBio, and Karuna Therapeutics in 2024, spending around $24 billion. Now, with the approval of Cobenfy, which was under Karuna Therapeutics, ...
NPR9mon
First new type of treatment for schizophrenia in decades - NPR
The Food and Drug Administration approved Cobenfy, ... Karuna Therapeutics, which was acquired by pharmaceutical heavyweight Bristol Myers Squibb for $14 billion dollars earlier this year.